REPLIMUNE GROUP INC (REPL)

REPL Crosses Above Key Moving Average Level

Replimune Announces $100 Million Private Placement Financing

- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional...

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first...

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response...

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of...

Replimune Group is Now Oversold (REPL)

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024

REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024.

REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Replimune Group (NASDAQ:REPL) just reported results for the fourth quarter of 2...

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed...

Oversold Conditions For Replimune Group (REPL)

Commit To Buy Replimune Group At $5, Earn 10.2% Annualized Using Options

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in...

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization ...

Replimune Group GAAP EPS of -$0.77 beats by $0.16 (NASDAQ:REPL)

Replimune Group reported Q3 2024 financial results, beating expectations with a GAAP EPS of -$0.77.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

Commit To Buy Replimune Group At $7.50, Earn 31.3% Annualized Using Options

Oversold Conditions For Replimune Group (REPL)

Why Is Replimune (REPL) Stock Down 48% Today?

Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints.

Replimune shares crash as skin cancer candidate fails trial (NASDAQ:REPL)

Replimune shares plummeted after their RP1 candidate failed to meet primary endpoints in a trial for treating a type of skin cancer, causing concerns for...

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to...